February 20, 2019
Xencor pauses testing leukemia bispecific antibody molecule as FDA inspects two possibly related deaths
Xencor has put on hold one of its studies on myeloid leukemia CD123 x CD3 bispecific antibody molecule XmAb14045, until the FDA lifts the hold, the company said Wednesday in a press release.